No Detail Found!

Efficacy of febuxostat with allopurinol in chronic kidney disease patients: a comparative study

Author(s)
MUHAMMAD AHMAD Department of Nephrology, Allied Hospital Faisalabad,Pakistan
IJAZ NABI Faisalabad institute of cardiology,Faisalabad,Pakistan
SALMAN MEHMOOD Department of Nephrology, Allied Hospital Faisalabad,Pakistan
NOUMAN HAMEED SHEIKH Department of Nephrology, DHQ Teaching Hospital/ Medical College,Gujranwala,Pakistan
RANA ZAHID HAFEEZ Department of Nephrology, Mustashfa Al Noor,Makkah,
RASHID IQBAL Department of Nephrology, Allied Hospital Faisalabad,Pakistan
Abstract
Efficacy of febuxostat with allopurinol in patients of chronic kidney disease Methods: 80 subjects with chronic kidney disease, 20 to 70 years of age with both gender were included. Patients of acute kidney injuries (AKI), acute nephritis, or rapidly progressive glomerulonephritis, liver dysfunction and alcohol abuse were excluded. Group A received febuxostat 40 mg/day for 3 months. Group B patients received allopurinol 100 mg/day for 3 months. Blood samples were sent to the laboratory for serum uric acid level. Results: The mean ± SD age of women in group A and B was 41.8 ± 12.8 and 41.2 ± 10.8 years respectively. Out of 80 cases, 53 (66.3%) were between 20 to 40 years of age. In this study, 55 cases (68.8%) were males and 25 (31.3%) were females. M:F ratio was 2.2:1. This study showed that febuxostat is more effective in reducing uric acid as compared to allopurinol i.e. 72.5% and 45% respectively with p-value of 0.012. Conclusion: Febuxostat is more effective in reducing uric acid as compared to allopurinol in chronic kidney disease cases.
Publication Details
Page(s) 160-161
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 05, Year: 2022

Request the full text from PASTIC

Keywords
Chronic kidney disease, Serum Uric acid, febuxostat.
References
Zheng C,Wang J,Chen T .2019 .Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. Sci Rep, 9 : 2694.
Fernandez FB,Sarafidis P,Kanbay M .2020 .SGLT2 inhibitors for nondiabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J, 13(5) : 728-33.
Ameen ,Kashif MA .2016 .To compare anti-albumin urea effects of valsartan alone with combination of valsartan and amlodipine in patients of chronic kidney disease. Pak J Med Sci, 32(3) : 613-16.
Lin T,Hung LY,Chen Y .2019 .Effects of febuxostat on renal function in patients with chronic kidney disease. A systemic review nad metaanalysis. Medicine (Baltimore), 98(29) : e16311.
Zeng XX,Tang Y,Hu K .2018 .Efficacy of febuxostat inhyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials. A PRISMA-compliant article. Medicine (Baltimore), 97(13) : e0161.
Peng Y,Tain Y,Lee C .2020 .Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep, 10 : 107-34.
Becker MA,Kisicki J,Khosravan R .2004 .a noval non-purine, selective inhibitor of xanthine oxidose, is safe and decreases serum urate in healthy volunteers. Nucleosides nucleotides nucleic acids, 23 : 1111-16.
Omori H,Kawada N,Inoue K. .2012 .Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol, 16 : 549-56.
.2011 .. Am J Med, 124 : 155-63.
Sakai Y,Otsuka T,Ohno D .2014 .Febuxostat for treating allopurinolresistant hyperuricemia in patients with chronic kidney disease. Ren Fail, 36 : 225-31.
Tsuruta Y,Mochizuki T,Moriyama T .2014 .Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol, 33 : 1643-48.
Perez-Ruiz Borghi C,F Borghi C .2016 .Urate lowering therapies in the treatment of gout: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci, 20 : 983-92.
0

Citations

0

Downloads

88

Views